Radioimmunotherapy (RIT) is a safe and effective therapeutic option for patients with indolent B-cell non-Hodgkin lymphomas (NHL), in both up-front and relapsed/refractory settings. Two approved agents (90Y-ibritumomab tiuxetan and 131I-tositumomab) are available in the United States. Both target CD20 with similar clinical outcomes but with unique clinical considerations and radiation precautions due to the use of varying radioisotopes.
Methods
This paper reviews the available evidence for these approved RIT agents and examines the recently published and ongoing clinical trials of potential novel indications for aggressive B-cell NHL.
Results
A pretreatment biodistribution evaluation required before administering the 90Y-ibritumomab tiuxetan therapeutic dose has been removed, which once limited its usage. The potential clinical applications of RIT include relapsed/refractory indolent B-cell NHL, diffuse large B-cell lymphoma, indolent lymphoma in the frontline setting, and mantle cell lymphoma. Multiple novel RIT agents are in preclinical and clinical development, and the addition of radiosensitizers or external-beam radiotherapy may act in synergy with RIT for both indolent and aggressive lymphomas. The risk of treatment-related myelodysplastic syndrome does not appear to be higher in patients treated with RIT over those receiving chemotherapy alone.
Conclusions
RIT is a safe, effective, and significantly underutilized therapy for patients with B-cell NHL, and many studies have demonstrated the efficacy of 90Y-ibritumomab tiuxetan and 131I-tositumomab for relapsed/refractory indolent B-cell lymphomas. Continued research to establish its efficacy for other lymphoma subtypes is warranted.
References
1.
DixonK.L.. The radiation biology of radioimmunotherapy.Nucl Med Commun.2003; 24(9): 951–957.
2.
WitzigT.E., GordonL.I., CabanillasF.. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory lowgrade, follicular, or transformed B-cell non-Hodgkin's lymphoma.J Clin Oncol.2002; 20(10): 2453–2463.
3.
KaminskiM.S., ZelenetzA.D., PressO.W.. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.J Clin Oncol.2001; 19(19): 3918–3928.
4.
KylstraJ.W., WitzigT.E., HuangM.. Discriminatory power of the 111-indium scan (111-In) in the prediction of altered biodistribution of radio-immunoconjugate in the 90-yttrium ibritumomab tiuxetan therapeutic regimen: meta-analysis of five clinical trials and 9 years of post-approval safety data.J Clin Oncol.2011; 29(15 suppl): 8048. Abstract.
5.
WagnerH.N.Jr, WisemanG.A., MarcusC.S.. Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with (90)Ylabeled anti-CD20 monoclonal antibody.J Nucl Med.2002; 43(2): 267–272.
6.
FriedbergJ.W., FisherR.I.. Iodine-131 tositumomab (Bexxar): radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin's lymphoma.Expert Rev Anticancer Ther.2004; 4(1): 18–26.
7.
KaminskiM.S., EstesJ., ZasadnyK.R.. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.Blood.2000; 96(4): 1259–1266.
8.
VoseJ.M., WahlR.L., SalehM.. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas.J Clin Oncol.2000; 18(6): 1316–1323.
9.
GockermanJ., GregoryS., HarwoodS.. Interim efficacy results of Bexxar in a large multicenter expanded access study.Proc Am Soc Clin Oncol.2001: 20(pt 1): 285a. Abstract 1137.
10.
HorningS.J., YounesA., JainV.. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.J Clin Oncol.2005; 23(4): 712–719.
11.
WisemanG.A., GordonL.I., MultaniP.S.. Ibritumomab tiuxetan radioimmunotherapy for patients with relapsed or refractory non-Hodgkin lymphoma and mild thrombocytopenia: a phase II multicenter trial.Blood.2002; 99(12): 4336–4342.
12.
WitzigT.E., FlinnI.W., GordonL.I.. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma.J Clin Oncol.2002; 20(15): 3262–3269.
13.
GordonL.I., WitzigT., MolinaA.. Yttrium 90-labeled ibritumomab tiuxetan radioimmunotherapy produces high response rates and durable remissions in patients with previously treated B-cell lymphoma.Clin Lymphoma.2004; 5(2): 98–101.
14.
EmmanouilidesC., WitzigT.E., GordonL.I.. Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.Leuk Lymphoma.2006; 47(4): 629–636.
15.
BachyE., BriceP., DelarueR.. Long-term follow-up of patients with newly diagnosed follicular lymphoma in the prerituximab era: effect of response quality on survival. A study from the groupe d'etude des lymphomes de l'adulte.J Clin Oncol.2010; 28(5): 822–829.
16.
MorschhauserF., RadfordJ., Van HoofA.. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.J Clin Oncol.2008; 26(32): 5156–5164.
17.
PressO.W., UngerJ.M., BrazielR.M.. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group Protocol S9911.Blood.2003; 102: 1606–1612.
18.
HainsworthJ.D., SpigelD.R., MarkusT.M.. Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium.Clin Lymphoma Myeloma.2009; 9(3): 223–228.
19.
JacobsS.A., SwerdlowS.H., KantJ.. Phase II trial of short-course CHOP-R followed by 90Y-ibritumomab tiuxetan and extended rituximab in previously untreated follicular lymphoma.Clin Cancer Res.2008; 14(21): 7088–7094.
20.
McLaughlinP., NeelapuS., FanaleM.. R-FND followed by radioimmunotherapy for high-risk follicular lymphoma.Blood (ASH Annual Meeting Abstracts).2008; 112(11): 3056.
21.
KarmaliR., KassarM., JimenezA.. Update on a prospective study evaluating the safety and efficacy of combination therapy with fludarabine, mitoxantrone and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front line therapy for patients with indolent lymphomas.Blood (ASH Annual Meeting Abstracts).2010; 116(21): 3946.
22.
ZinzaniP.L., TaniM., PulsoniA.. A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by 90Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.Ann Oncol.2012; 23(2): 415–420.
23.
RoseA.C., GarrettG., SewardM.. A systematic review and meta-analysis of radioimmunotherapy consolidation for untreated patients with follicular lymphoma (FL).Blood (ASH Annual Meeting Abstracts).2011; 118(21): 101.
24.
KaminskiM.S., TuckM., EstesJ.. 131I-tositumomab therapy as initial treatment for follicular lymphoma.N Engl J Med.2005; 352(5): 441–449.
25.
KaminskiM.S., TuckM., EstesJ.. Tositumomab and iodine I-131 tositumomab for previously untreated, advanced stage, follicular lymphoma: median 10 year follow-up results.Blood (ASH Annual Meeting Abstracts).2009; 114(22): 3759.
26.
PicaG., NatiS., VitoloU.. Safety and efficacy of 90Y ibritumomab tiuxetan (Zevalin) for untreated follicular non-Hodgkin's lymphoma (FL) patients, an Italian cooperative study.Blood (ASH Annual Meeting Abstracts).2011; 118(21): 100.
27.
ZinzaniP.L., TaniM., FantiS.. A phase 2 trial of fludarabine and mitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan for patients with previously untreated, indolent, nonfollicular, non-Hodgkin lymphoma.Cancer.2008; 112(4): 856–862.
28.
PressO.W., UngerJ.M., BrazielR.M.. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin's lymphoma: five-year follow-up of Southwest Oncology Group Protocol S9911.J Clin Oncol.2006; 24(25): 4143–4149.
29.
LeonardJ.P., ColemanM., KostakogluL.. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.J Clin Oncol.2005; 23: 5696–5704.
30.
FowlerN.H., NeelapuS.S., FanaleM.A.. Phase II study with R-FND followed by 90-Y ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance for untreated high-risk follicular lymphoma.Blood (ASH Annual Meeting Abstracts).2011; 118(21): 99.
31.
MorschhauserF., IllidgeT., HugloD.. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation.Blood.2007; 110(1): 54–58.
32.
ZinzaniP.L., TaniM., FantiS.. A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.Ann Oncol.2008; 19(4): 769–773.
33.
HamlinP.A., MoskowitzC.H., WegnerB.. Sequential RCHOP and yttrium-90 ibritumomab tiuxetan (RIT) is a highly effective regimen for high risk elderly patients with untreated DLBCL.Ann Oncol.2008; 19(suppl 4): iv100. Abstract 054.
34.
ZinzaniP.L., RossiG., FranceschettiS.. Phase II trial of short-course RCHOP followed by 90Y-ibritumomabtiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients.Clin Cancer Res.2010; 16(15): 3998–4004.
35.
FriedbergJ.W., UngerJ.M., BurackW.R.. RCHOP with iodine-131 tositumomab consolidation for advanced stage diffuse large B-cell lymphoma (DLBCL): Southwest Oncology Group Protocol S0433.Blood (ASH Annual Meeting Abstracts).2010; 116(21): 590.
36.
WangM., OkiY., ProB.. Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.J Clin Oncol.2009; 27: 5213–5218.
37.
ZelenetzA.D., NoyA., Pandit-TaskarN.. Sequential radioimmunotherapy with tositumomab/Iodine I131 tositumomab followed by CHOP for mantle cell lymphoma demonstrates RIT can induce molecular remissions.J Clin Oncol.2006; 24(18 suppl): 7560. Abstract.
38.
SmithM., ChenL., GordonL.I.. Phase II study of RCHOP and 90Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma (E1499).J Clin Oncol.2006; 24(18 suppl): 7503. Abstract.
39.
BeavenA.W., SheaT.C., MooreD.T.. A phase I study evaluating ibritumomab tiuxetan (Zevalin®) in combination with bortezomib (Velcade®) in relapsed/refractory mantle cell and low grade B-cell non-Hodgkin lymphoma.Leuk Lymphoma.2012; 53(2): 254–258.
40.
IllidgeT.M., BayneM., BrownN.S.. Phase 1/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy.Blood.2009; 113: 1412–1421.
41.
ShahJ., WangW., HarroughV.D.. Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma.Leuk Lymphoma.2007; 48(9): 1736–1744.
42.
KaminskiM.S., RadfordJ.A., GregoryS.A.. Retreatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.J Clin Oncol.2005; 23(31): 7985–7993.
43.
IllidgeT.M., PettengellR., BayneM.. Fractionated 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy as an initial therapy of follicular lymphoma: first results from a phase II study in patients requiring treatment according to GELF/BNLI criteria.Blood (ASH Annual Meeting Abstracts).2011; 118(21): 102.
44.
JankowitzR., JoyceJ., JacobsS.A.. Anaphylaxis after administration of ibritumomab tiuxetan for follicular non-hodgkin lymphoma.Clin Nucl Med.2008; 33(2): 94–96.
45.
MorschhauserF., Kraeber-BodéréF., WegenerW.A.. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma.J Clin Oncol.2010; 28(23): 3709–3716.
46.
MaD., McDevittM.R., BarendswaardE.. Radioimmunotherapy for model B cell malignancies using 90Y-labeled anti-CD19 and anti-CD20 monoclonal antibodies.Leukemia.2002; 16(1): 60–66.
47.
ValleraD.A., ElsonM., BrechbielM.W.. Radiotherapy of CD19 expressing Daudi tumors in nude mice with Yttrium-90-labeled anti-CD19 antibody.Cancer Biother Radiopharm.2004; 19(1): 11–23.
MichelR.B., RosarioA.V., BrechbielM.W.. Experimental therapy of disseminated B-Cell lymphoma xenografts with 213Bi-labeled anti-CD74.Nucl Med Biol.2003; 30(7): 715–723.
50.
OrcuttK.D., NasrK.A., WhiteheadD.G.. Biodistribution and clearance of small molecule hapten chelates for pretargeted radioimmunotherapy.Mol Imaging Biol.2011; 13(2): 215–221.
51.
SharkeyR.M., KaracayH., JohnsonC.R.. Pretargeted versus directly targeted radioimmunotherapy combined with anti-CD20 antibody consolidation therapy of non-Hodgkin lymphoma.J Nucl Med.2009; 50(3): 444–453.
52.
JóhannssonJ., SpechtL., MejerJ.. Phase II study of palliative low-dose local radiotherapy in disseminated indolent non-Hodgkin's Lymphoma and chronic lymphocytic leukemia.Int J Radiat Oncol Biol Phys.2002; 54(5): 1466–1470.
53.
HaasR.L., PoortmansP., de JongD.. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas.J Clin Oncol.2003; 21(13): 2474–480.
54.
LuthyS.K., NgA.K., SilverB.. Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma.Ann Oncol.2008; 19(12): 2043–2047.
55.
BurdickM.J., NeumannD., PohlmanB.. External beam radiotherapy followed by 90Y ibritumomab tiuxetan in relapsed or refractory bulky follicular lymphoma.Int J Radiat Oncol Biol Phys.2011; 79(4): 1124–1130.
56.
TomblynM.. Addition of low-dose, involved-field external beam radiotherapy just prior to radioimmunotherapy for B-cell lymphoma: “priming” cell death pathways.J Clin Oncol.2011; 29(suppl): e18533. Abstract.
57.
GuptaD., CrosbyM.E., AlmasanA.. Regulation of CD20 expression by radiation-induced changes in intracellular redox status.Free Radic Biol Med.2008; 44(4): 614–623.
58.
CzuczmanM.S., EmmanouilidesC., DarifM.. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy.J Clin Oncol.2007; 25(27): 4285–4292.
59.
Pedersen-BjergaardJ., Ersb0llJ., SørensenH.M.. Risk of acute nonlymphocytic leukemia and preleukemia in patients treated with cyclophosphamide for non-Hodgkin's lymphomas: comparison with results obtained in patients treated for Hodgkin's disease and ovarian carcinoma with other alkylating agents.Ann Intern Med.1985; 103(2): 195–200.
60.
MortonL.M., CurtisR.E., LinetM.S.. Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype.J Clin Oncol.2010; 28(33): 4935–4944.
